Update 2021: COVID-19 aus Sicht der Nephrologie

Seit nunmehr über einem Jahr hält die SARS-CoV-2-Pandemie Alltagsleben und Gesundheitssystem fest in ihrem Griff, und Studien zum Virus und COVID-19 dominieren die wissenschaftliche Literatur. Entsprechend gibt es auch zur Relevanz der Nieren und Nierenerkrankungen bei COVID-19 neue Erkenntnisse, die in einigen Schwerpunkten hier kurz vorgestellt werden sollen.

Abstract

Increasing insight into the clinical phenotype and mechanisms of SARS-CoV-2 infections and COVID-19 has identified damage of the kidneys as a key player in the course of the disease. This manuscript updates our previous summary with current knowledge on kidney involvement in COVID-19 and chronic kidney disease as a risk factor for severe COVID-19, as well as recommendations regarding SARS-CoV-2 vaccination for patients suffering from chronic kidney disease and after organ transplantation, respectively. populations, SARS-CoV-2 vaccination is strongly recommended for all patients suffering from chronic kidney disease and after kidney transplantation.

Schlüsselwörter

COVID-19 - Chronische Nierenerkrankung - SARS-COV-2-Impfung

Key words

COVID-19 - chronic kidney disease - SARS-CoV-2 vaccination

Publication History

Article published online:
13 July 2021

• Literatur

• 1 Nugent J, Aklilu A, Yamamoto Y. et al. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. JAMA Netw Open 2021; 4: e211095
• 2 Pakhchanian H, Raiker R, Mukherjee A. et al. Outcomes of COVID-19 in CKD Patients: A Multicenter Electronic Medical Record Cohort Study. CJASN 2021;
• 3 Robert-Koch-Institut. Epidemiologisches Bulletin 2021 Feb. 2021: 74
• 4 Shaikh A, Zeldis E, Campbell KN. et al. Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis. CJASN 2021; 16: 290-292
• 5 van Kampen JJA, van de Vijver DAMC, Fraaij PLA. et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nature Communications 2021; 12 (267)
• 6 Labriola L, Scohy A, Seghers F. et al. A Longitudinal, 3-Month Serologic Assessment of SARS-CoV-2 Infections in a Belgian Hemodialysis Facility. CJASN 2020;
• 7 Glenn DA, Hegde A, Kotzen E. et al. Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease. Kidney Int Rep 2021;
• 8 Chang YT, Ling TC, Cheng YY. et al. Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial. Vaccines (Basel) 2021; 9
• 9 Boyarsky BJ, Werbel WA, Avery RK. et al. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA 2021;